Third Point Reports 5.8% Strata Critical Medical Stake, Says Company Should Explore A Sale
Dan Loeb's firm moved from a passive to an active ownership filing, calling the stock undervalued and the business too small for its overhead.
Third Point LLC and its chief executive, Daniel S. Loeb, disclosed 5,126,511 shares of Strata Critical Medical, or 5.8% of the class, in a Schedule 13D, the SEC ownership filing used by investors who may seek to influence a company. The filing, dated Thursday, says the company should explore strategic alternatives, including a sale run by an investment bank.
What the Schedule 13D says
Item 4 says Third Point bought the shares for investment purposes and believes the stock is undervalued. It describes the underlying business as strong, but "not of a scale to support its current overhead," and says management incentive options are not aligned with creating shareholder value.
The filing says the company should consider "a potential sale of the Issuer managed by a reputable investment banking firm." The filers may talk with management, the board, other shareholders or third parties, and may swap information under confidentiality agreements.
They also say they may buy more shares or sell some or all of their stake, depending on factors including the share price and the company's response to any communications.
Both Third Point and Loeb report shared voting power over all 5,126,511 shares and none solely. The 5.8% figure assumes 88,466,806 shares outstanding as of July 28, 2026, taken from the company's 10-Q filed August 4, 2026. The funds spent $24,452,374 of their own investment capital on the shares.
What changes for holders
Third Point previously reported the position on a passive Schedule 13G, filed August 11, 2025 and amended November 14, 2025. The switch to a 13D means the firm now says it may press the company on strategy. Strata Critical Medical is the successor to Blade Air Mobility.
The trading exhibit lists eight transactions across two Third Point funds since August 31, 2026. On October 12, Third Point Master Fund bought 38,343 shares at $4.55 and Third Point Ultra Master Fund bought 20,400 at the same price. On October 13, they bought 42,668 and 25,100 shares at $4.53.
Earlier trades were transfers between the two funds: 8,300 shares at $5.66 on August 31 and 35,200 at $5.11 on September 30. Market data showed the shares closing at $4.34 on Thursday, for a market value of $379 million.
What to watch
The next steps are whether the board responds to the call for strategic alternatives and whether Third Point amends the filing after further buying or selling.
The filing says the investment will be reviewed on a continuing basis, so any amendment would show whether Third Point has added to or cut the 5,126,511 shares.